Background: The hepatokine fetuin-A, released by the human liver, promotes pro-inflammatory effects of perivascular fat. The involvement of inflammation in type 2 diabetes mellitus (T2DM) can affect the kidney and contribute to the development of diabetic kidney disease. Therefore we examined the association of urinary fetuin-A protein fragments with renal damage in T2DM patients. Methods: Urinary peptides of 1491 individuals using proteome data available from the human urine proteome database were analysed. Prediction of proteases involved in urinary peptide generation was performed using the Proteasix tool. Results: We identified 14 different urinary protein fragments that belong to the region of the connecting peptide (amino ac...
Background: In end-stage renal disease, fetuin-A has been demonstrated to be reduced and inversely r...
Mechanisms underlying the onset and progression of nephropathy in diabetic patients are not fully el...
Aims: To seek urinary peptides as biomarkers distinguishing type 2 diabetes mellitus (T2DM) patients...
Varying degrees of renal injury could lead to different changes in urinary protein composition. We w...
We analyzed the urine samples of patients with type 2 diabetes at various stages of diabetic nephrop...
Treatment with empagliflozin, an inhibitor of the sodium/glucose cotransporter 2 (SGLT2), is associa...
Treatment with empagliflozin, an inhibitor of the sodium/glucose cotransporter 2 (SGLT2), is associa...
Background: Nephropathy associated with diabetes is a severe complication that cause slow kidneys d...
Diabetic nephropathy (DN) is a complication associated with diabetes, leading to end-stage renal dis...
Diabetic kidney disease is the leading cause of end-stage renal disease worldwide. The early mechani...
Background Fetuin-A is a hepatic secretory protein that binds to insulin receptors and inhibits insu...
Microalbuminuria is considered the first clinical sign of kidney dysfunction and is associated with ...
Fetuins are blood glycoproteins manufactured in the liver and secreted into the bloodstream. These g...
We analyzed the urine samples of patients with type 2 diabetes at various stages of diabetic nephrop...
The aim of this study was to establish a peptidomic profle based on LC-MS/MS and random forest (RF) ...
Background: In end-stage renal disease, fetuin-A has been demonstrated to be reduced and inversely r...
Mechanisms underlying the onset and progression of nephropathy in diabetic patients are not fully el...
Aims: To seek urinary peptides as biomarkers distinguishing type 2 diabetes mellitus (T2DM) patients...
Varying degrees of renal injury could lead to different changes in urinary protein composition. We w...
We analyzed the urine samples of patients with type 2 diabetes at various stages of diabetic nephrop...
Treatment with empagliflozin, an inhibitor of the sodium/glucose cotransporter 2 (SGLT2), is associa...
Treatment with empagliflozin, an inhibitor of the sodium/glucose cotransporter 2 (SGLT2), is associa...
Background: Nephropathy associated with diabetes is a severe complication that cause slow kidneys d...
Diabetic nephropathy (DN) is a complication associated with diabetes, leading to end-stage renal dis...
Diabetic kidney disease is the leading cause of end-stage renal disease worldwide. The early mechani...
Background Fetuin-A is a hepatic secretory protein that binds to insulin receptors and inhibits insu...
Microalbuminuria is considered the first clinical sign of kidney dysfunction and is associated with ...
Fetuins are blood glycoproteins manufactured in the liver and secreted into the bloodstream. These g...
We analyzed the urine samples of patients with type 2 diabetes at various stages of diabetic nephrop...
The aim of this study was to establish a peptidomic profle based on LC-MS/MS and random forest (RF) ...
Background: In end-stage renal disease, fetuin-A has been demonstrated to be reduced and inversely r...
Mechanisms underlying the onset and progression of nephropathy in diabetic patients are not fully el...
Aims: To seek urinary peptides as biomarkers distinguishing type 2 diabetes mellitus (T2DM) patients...